Kairos Pharma Reports Zero Grade 3+ Toxicities in Phase 1 Trial of ENV-105 for EGFR-Mutated Lung Cancer
核心洞察
Kairos Pharma (搜索) announced interim Phase 1 safety data showing zero Grade 3 or higher adverse events from ENV-105 across 13 treated patients with EGFR (搜索)-mutated NSCLC.
ENV-105 (carotuximab), a first-in-class CD105 (搜索) antibody, is being evaluated in combination with osimertinib to overcome acquired resistance in advanced lung cancer.
The EGFR (搜索)-mutated NSCLC market is valued at approximately $10 billion, with no FDA-approved agent currently available to reverse osimertinib resistance.
Kairos Pharma (搜索), Ltd. (NYSE American: KAPA) has announced compelling interim safety data from its ongoing Phase 1 clinical trial evaluating ENV-105 (carotuximab) in combination with osimertinib (AstraZeneca's Tagrisso®) in patients with advanced EGFR (搜索)-mutated non-small cell lung cancer (搜索) (NSCLC). The data, reported on July 15, 2026, show zero serious adverse events — defined as Grade 3 or higher — associated with ENV-105 across 13 treated patients to date, supporting continued progression toward an early efficacy readout.
The findings represent a pivotal milestone in Kairos Pharma (搜索)'s lead program focused on resensitizing patients who have acquired resistance to osimertinib, the global standard-of-care for EGFR (搜索)-mutated NSCLC. "Our goal is not simply to complete a Phase 1 trial; it is to deliver a re-sensitization solution that changes the post-progression treatment paradigm and positions Kairos as the essential complement to the EGFR-targeted therapy market with this clean safety profile now confirmed across 13 patients," said Dr. John Yu, Chief Executive Officer of Kairos Pharma.
The Unmet Need in EGFR (搜索)-Mutated NSCLC
Non-small cell lung cancer (搜索) accounts for approximately 85% of all lung cancer diagnoses globally. Within this population, EGFR (搜索)-mutated patients represent the most commercially important and genetically actionable subpopulation. The EGFR-NSCLC market is valued at approximately $10 billion across leading current markets, growing at a compound annual growth rate of 10.5% and projected to exceed $13 billion by 2030.
Osimertinib (Tagrisso®) is the gold-standard, first-line therapy for this patient population, generating approximately $6 billion in annual sales. Despite its initial efficacy, resistance to the drug is inevitable. Once a patient progresses on osimertinib, therapeutic options are limited, and survival outcomes are inferior. Currently, no FDA-approved agent is specifically designed to reverse or overcome osimertinib resistance and restore drug sensitivity.
Mechanism of Action: Targeting CD105 (搜索)
Kairos Pharma (搜索)'s scientific approach is grounded in the observation that CD105 (搜索) (endoglin (搜索)) is pathologically elevated in patients who develop osimertinib resistance, and its overexpression drives one of the core resistance signaling pathways. ENV-105 (carotuximab) is a first-in-class CD105 antibody that blocks the signaling of this overexpressed protein, mechanistically dismantling the resistance phenotype and creating the biological conditions for osimertinib sensitivity.
This strategy aims to extend progression-free survival, preserve quality of life, and fundamentally increase the clinical utility of the world's most prescribed EGFR (搜索)-targeted therapy. If successful, ENV-105 would not compete with osimertinib — it would extend its commercial life across the entire EGFR-mutated patient population.
Interim Safety Data and Trial Design
The interim safety analysis of the Phase 1 trial evaluating ENV-105 plus osimertinib in EGFR (搜索)-mutated advanced NSCLC patients demonstrates a clean early safety profile in the 13 patients treated with combination therapy. The trial is designed to assess safety, tolerability, and the recommended Phase 2 dose, with adverse events evaluated under Common Terminology Criteria for Adverse Events (CTCAE) 5.0 and dose-limiting toxicities monitored during the initial treatment cycles. All side effects were manageable with standard supportive care.
Clinical Validation Beyond Lung Cancer
ENV-105's clinical validation extends beyond lung cancer. In an ongoing Phase 2 trial for castrate-resistant prostate cancer (搜索), ENV-105 delivered median progression-free survival exceeding 13 months, a significant improvement over standard of care. This suggests that the CD105 (搜索) suppression mechanism translates into durable clinical benefit across fundamentally different tumor types and resistance contexts.
"ENV-105 continues to be extremely well tolerated, now across two very different indications," said Dr. Neil Bhowmick, Chief Science Officer of Kairos Pharma (搜索). "As we continue to showcase ENV-105's potential for targeting drug resistance, this data is another important milestone in achieving our goal to ultimately provide better patient care over a longer term."
The scientific rationale for targeting CD105 (搜索) is well-established: CD105 is a validated driver of resistance and disease relapse across multiple cancer types, including EGFR (搜索)-driven NSCLC, and preclinical models have already confirmed ENV-105's capacity to sensitize tumors to both radiation and hormone therapy.